Control of Breathing and Pompe Disease

呼吸控制和庞贝病

基本信息

  • 批准号:
    10152637
  • 负责人:
  • 金额:
    $ 59.32万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-02-15 至 2025-04-30
  • 项目状态:
    未结题

项目摘要

Project Summary / Abstract: Pompe disease results from mutations in the gene for acid α-glucosidase (GAA) – an enzyme necessary to degrade lysosomal glycogen. Early-onset disease occurs in the absence of functional GAA which leads to cardiorespiratory failure early in life. Late-onset disease is associated with reduced GAA activity and gradual progression to respiratory failure. Work from our first two grant cycles indicates neural involvement in respiratory failure in Gaa-/- mice and Pompe patients. This is relevant since the standard of care – intravenous enzyme therapy using recombinant GAA - does not reach the central nervous system (CNS) and patients still progress to respiratory failure. Our overarching hypothesis is that adeno-associated virus (AAV) therapy is capable of restoring life-long GAA expression throughout the CNS, skeletal and cardiac muscle, thereby preserving cardiorespiratory function and prolonging life. Aim 1 focuses on AAV therapy for early-onset disease which requires early life treatments that can prevent both respiratory and cardiac failure. To better study this problem, we created a Gaa null (Gaa-/-) rat model which recapitulates the early onset phenotype with cardiorespiratory pathology and early mortality. Preliminary data indicate that neonatal AAV-GAA therapy (desmin promoter, AAV9 serotype) evokes no detectable immune response, mitigates cardiac and respiratory pathology and prevents early death. Thus, we hypothesize that a single intravenous AAV-GAA dose in young rats can drive persistent and widespread GAA expression and extend the Pompe rat lifespan. Aim 2 addresses late onset Pompe disease in which respiratory failure is the primary cause of mortality. Based on data from our first two grant cycles we hypothesize that neural directed AAV-GAA therapy in adult Pompe rats is sufficient to prevent respiratory decline and extend the lifespan. By packaging AAV-GAA with muscle (creatine kinase 8), neural (synapsin) or tissue specific (muscle and neural, desmin) promoters, and delivering the vector intrathecally, intravenously, or both, we can drive GAA expression in a manner that will determine if neural correction is necessary and sufficient to prevent decline. The aforementioned Gaa null rat will be used to test proof-of-concept for neural vs. muscle correction in the absence of endogenous GAA activity. We will also use another new Pompe rat model in which CRISPR/cas9 has been used to insert the most common human gene mutation causing late-onset Pompe disease (IVS1) into the rat genome. This is important because the IVS1 mutation leads to low but not absent GAA activity and is associated with delayed progression to respiratory failure. The proposed work is significant because current therapeutic strategies in Pompe disease only delay disease progression with eventual respiratory failure. The strategies proposed here will also contribute to the broader goal of advancing gene therapy for neurodegenerative conditions and autosomal recessive diseases.
项目摘要/摘要: 庞贝病是由酸性 α-葡萄糖苷酶 (GAA) 基因突变引起的,GAA 是一种必需的酶。 降解溶酶体糖原。早发性疾病发生在缺乏功能性 GAA 的情况下,从而导致 生命早期出现心肺衰竭。晚发性疾病与 GAA 活性降低和逐渐 进展为呼吸衰竭。我们前两个资助周期的工作表明神经参与 Gaa-/- 小鼠和庞贝氏症患者的呼吸衰竭。这是相关的,因为护理标准 – 静脉注射 使用重组 GAA 的酶疗法 - 无法到达中枢神经系统 (CNS),患者仍然 进展为呼吸衰竭。我们的首要假设是腺相关病毒(AAV)疗法 能够恢复整个中枢神经系统、骨骼和心肌的终生 GAA 表达,从而 保护心肺功能,延长寿命。目标 1 侧重于早发型 AAV 治疗 需要早期治疗的疾病,以预防呼吸衰竭和心力衰竭。为了更好 为了研究这个问题,我们创建了 Gaa null (Gaa-/-) 大鼠模型,该模型概括了早发表型 心肺病理学和早期死亡率。初步数据表明新生儿 AAV-GAA 治疗 (结蛋白启动子,AAV9 血清型)不会引起可检测到的免疫反应,减轻心脏和呼吸系统的反应 病理并防止过早死亡。因此,我们假设单次静脉注射 AAV-GAA 剂量对年轻人来说 大鼠可以驱动持久且广泛的 GAA 表达并延长庞贝大鼠的寿命。目标2 解决迟发性庞贝病,其中呼吸衰竭是死亡的主要原因。基于 根据我们前两个资助周期的数据,我们假设对成年 Pompe 大鼠进行神经定向 AAV-GAA 治疗 足以防止呼吸衰退并延长寿命。通过将 AAV-GAA 与肌肉包装在一起 (肌酸激酶 8)、神经(突触蛋白)或组织特异性(肌肉和神经、结蛋白)启动子,以及递送 通过鞘内、静脉内或两者,我们可以驱动 GAA 表达,以确定是否 神经矫正对于防止衰退是必要且充分的。将使用前述的Gaa无效大鼠 测试在缺乏内源性 GAA 活性的情况下神经与肌肉校正的概念验证。我们将 还使用另一种新的 Pompe 大鼠模型,其中使用 CRISPR/cas9 插入最常见的 导致迟发性庞贝病(IVS1)的人类基因突变进入大鼠基因组。这很重要 因为 IVS1 突变导致 GAA 活性低但并非缺失,并且与延迟相关 进展为呼吸衰竭。拟议的工作意义重大,因为当前的治疗策略 庞贝病只会延迟疾病进展,最终导致呼吸衰竭。这里提出的策略 还将有助于推进神经退行性疾病基因治疗的更广泛目标, 常染色体隐性遗传疾病。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

BARRY J BYRNE其他文献

BARRY J BYRNE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('BARRY J BYRNE', 18)}}的其他基金

Phase II Study of AAV9-GAA Gene Transfer in Pompe Disease
AAV9-GAA 基因转移治疗庞贝病的 II 期研究
  • 批准号:
    9444518
  • 财政年份:
    2015
  • 资助金额:
    $ 59.32万
  • 项目类别:
Spinal and brainstem respiratory neurons in Pompe disease
庞贝病中的脊髓和脑干呼吸神经元
  • 批准号:
    8426726
  • 财政年份:
    2012
  • 资助金额:
    $ 59.32万
  • 项目类别:
Spinal and brainstem respiratory neurons in Pompe disease
庞贝病中的脊髓和脑干呼吸神经元
  • 批准号:
    8534315
  • 财政年份:
    2012
  • 资助金额:
    $ 59.32万
  • 项目类别:
Vector Core
矢量核心
  • 批准号:
    7669755
  • 财政年份:
    2009
  • 资助金额:
    $ 59.32万
  • 项目类别:
PHASE I TRIAL OF OCULAR SUBRETINAL INJECTION OF A RAAV2-CB - HRPE65
RAAV2-CB 眼部视网膜下注射的 I 期试验 - HRPE65
  • 批准号:
    7950730
  • 财政年份:
    2008
  • 资助金额:
    $ 59.32万
  • 项目类别:
CARDIAC AND SKELETAL MUSCLE IN BARTH SYNDROME
巴斯综合征中的心肌和骨骼肌
  • 批准号:
    7950710
  • 财政年份:
    2008
  • 资助金额:
    $ 59.32万
  • 项目类别:
AGLU03206 OPEN LABEL EXTENSION OF AGLU02704
AGLU03206 AGLU02704 的开放标签扩展
  • 批准号:
    7950754
  • 财政年份:
    2008
  • 资助金额:
    $ 59.32万
  • 项目类别:
AGLU03206 OPEN LABEL EXTENSION OF AGLU02704
AGLU03206 AGLU02704 的开放标签扩展
  • 批准号:
    7717143
  • 财政年份:
    2007
  • 资助金额:
    $ 59.32万
  • 项目类别:
Control of Breathing and Pompe Disease
呼吸控制和庞贝病
  • 批准号:
    9973263
  • 财政年份:
    2007
  • 资助金额:
    $ 59.32万
  • 项目类别:
CARDIAC AND SKELETAL MUSCLE IN BARTH SYNDROME
巴斯综合征中的心肌和骨骼肌
  • 批准号:
    7717084
  • 财政年份:
    2007
  • 资助金额:
    $ 59.32万
  • 项目类别:

相似海外基金

Developing a Young Adult-Mediated Intervention to Increase Colorectal Cancer Screening among Rural Screening Age-Eligible Adults
制定年轻人介导的干预措施,以增加农村符合筛查年龄的成年人的结直肠癌筛查
  • 批准号:
    10653464
  • 财政年份:
    2023
  • 资助金额:
    $ 59.32万
  • 项目类别:
Doctoral Dissertation Research: Estimating adult age-at-death from the pelvis
博士论文研究:从骨盆估算成人死亡年龄
  • 批准号:
    2316108
  • 财政年份:
    2023
  • 资助金额:
    $ 59.32万
  • 项目类别:
    Standard Grant
Determining age dependent factors driving COVID-19 disease severity using experimental human paediatric and adult models of SARS-CoV-2 infection
使用 SARS-CoV-2 感染的实验性人类儿童和成人模型确定导致 COVID-19 疾病严重程度的年龄依赖因素
  • 批准号:
    BB/V006738/1
  • 财政年份:
    2020
  • 资助金额:
    $ 59.32万
  • 项目类别:
    Research Grant
Transplantation of Adult, Tissue-Specific RPE Stem Cells for Non-exudative Age-related macular degeneration (AMD)
成人组织特异性 RPE 干细胞移植治疗非渗出性年龄相关性黄斑变性 (AMD)
  • 批准号:
    10294664
  • 财政年份:
    2020
  • 资助金额:
    $ 59.32万
  • 项目类别:
Sex differences in the effect of age on episodic memory-related brain function across the adult lifespan
年龄对成人一生中情景记忆相关脑功能影响的性别差异
  • 批准号:
    422882
  • 财政年份:
    2019
  • 资助金额:
    $ 59.32万
  • 项目类别:
    Operating Grants
Modelling Age- and Sex-related Changes in Gait Coordination Strategies in a Healthy Adult Population Using Principal Component Analysis
使用主成分分析对健康成年人群步态协调策略中与年龄和性别相关的变化进行建模
  • 批准号:
    430871
  • 财政年份:
    2019
  • 资助金额:
    $ 59.32万
  • 项目类别:
    Studentship Programs
Transplantation of Adult, Tissue-Specific RPE Stem Cells as Therapy for Non-exudative Age-Related Macular Degeneration AMD
成人组织特异性 RPE 干细胞移植治疗非渗出性年龄相关性黄斑变性 AMD
  • 批准号:
    9811094
  • 财政年份:
    2019
  • 资助金额:
    $ 59.32万
  • 项目类别:
Study of pathogenic mechanism of age-dependent chromosome translocation in adult acute lymphoblastic leukemia
成人急性淋巴细胞白血病年龄依赖性染色体易位发病机制研究
  • 批准号:
    18K16103
  • 财政年份:
    2018
  • 资助金额:
    $ 59.32万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Doctoral Dissertation Research: Literacy Effects on Language Acquisition and Sentence Processing in Adult L1 and School-Age Heritage Speakers of Spanish
博士论文研究:识字对西班牙语成人母语和学龄传统使用者语言习得和句子处理的影响
  • 批准号:
    1823881
  • 财政年份:
    2018
  • 资助金额:
    $ 59.32万
  • 项目类别:
    Standard Grant
Adult Age-differences in Auditory Selective Attention: The Interplay of Norepinephrine and Rhythmic Neural Activity
成人听觉选择性注意的年龄差异:去甲肾上腺素与节律神经活动的相互作用
  • 批准号:
    369385245
  • 财政年份:
    2017
  • 资助金额:
    $ 59.32万
  • 项目类别:
    Research Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了